Found: 17
Select item for more details and to access through your institution.
Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.
- Published in:
- European Radiology, 2021, v. 31, n. 7, p. 4794, doi. 10.1007/s00330-020-07457-6
- By:
- Publication type:
- Article
Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
- Published in:
- European Radiology, 2020, v. 30, n. 1, p. 186, doi. 10.1007/s00330-019-06351-0
- By:
- Publication type:
- Article
Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Extracorporeal photopheresis vs standard therapies for steroid‐refractory chronic graft‐vs‐host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
- Published in:
- Journal of Clinical Apheresis, 2021, v. 36, n. 4, p. 612, doi. 10.1002/jca.21901
- By:
- Publication type:
- Article
Treatment of Hepatocellular Carcinoma.
- Published in:
- Digestive Diseases, 2016, v. 34, n. 5, p. 597, doi. 10.1159/000445275
- By:
- Publication type:
- Article
Cytogenetic Assessment and Risk Stratification in Myelofibrosis with Optical Genome Mapping.
- Published in:
- Cancers, 2023, v. 15, n. 11, p. 3039, doi. 10.3390/cancers15113039
- By:
- Publication type:
- Article
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 5, p. 724, doi. 10.1111/ejh.13604
- By:
- Publication type:
- Article
Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: Results from the ColHai registry.
- Published in:
- Liver International, 2024, v. 44, n. 9, p. 2303, doi. 10.1111/liv.15970
- By:
- Publication type:
- Article
Advancing radiology reporting with large language models: Is GPT- 4 the LI- RADS game changer or just a wild card?
- Published in:
- Liver International, 2024, v. 44, n. 7, p. 1575, doi. 10.1111/liv.15952
- By:
- Publication type:
- Article
Predicting liver‐related serious adverse events in patients with primary biliary cholangitis‐related cirrhosis treated with obeticholic acid.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.
- Published in:
- Liver International, 2020, v. 40, n. 10, p. 2476, doi. 10.1111/liv.14587
- By:
- Publication type:
- Article
International and multicenter real‐world study of sorafenib‐treated patients with hepatocellular carcinoma under dialysis.
- Published in:
- Liver International, 2020, v. 40, n. 6, p. 1467, doi. 10.1111/liv.14436
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 6, p. 545, doi. 10.1159/000518104
- By:
- Publication type:
- Article
Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study.
- Published in:
- Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2024, v. 29, n. 3, p. 1, doi. 10.1016/j.aohep.2024.101489
- By:
- Publication type:
- Article
Comprehensive detection of CRLF2 alterations in acute lymphoblastic leukemia: a rapid and accurate novel approach.
- Published in:
- Frontiers in Molecular Biosciences, 2024, p. 1, doi. 10.3389/fmolb.2024.1362081
- By:
- Publication type:
- Article
Systematic review with meta‐analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2019, v. 49, n. 5, p. 482, doi. 10.1111/apt.15088
- By:
- Publication type:
- Article
Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment.
- Published in:
- Gastrointestinal Disorders, 2022, v. 4, n. 3, p. 141, doi. 10.3390/gidisord4030014
- By:
- Publication type:
- Article